Aminolevulinic Acid

證據等級: L5

預測適應症: 10 個

Aminolevulinic Acid: From High-Grade Glioma Visualization to Pre-Malignant Neoplasm Treatment

One-Sentence Summary

5-Aminolevulinic acid (5-ALA) is a naturally occurring amino acid and established photosensitizer precursor, globally approved for fluorescence-guided resection of high-grade gliomas (Gleolan®) and treatment of actinic keratosis (Levulan®), but currently holding no Singapore market authorization. The TxGNN model predicts it may be effective for the broader indication of Pre-Malignant Neoplasm (TxGNN score 96.01%), supported by 1 completed Phase 3 RCT directly targeting pre-malignant lesions and 20 publications spanning mechanistic, systematic review, and clinical evidence.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; globally approved for actinic keratosis (Levulan®) and high-grade glioma fluorescence-guided surgery (Gleolan®)
Predicted New Indication	Pre-Malignant Neoplasm
TxGNN Prediction Score	96.01%
Evidence Level	L2
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on well-established literature, 5-ALA is a naturally occurring intermediate in the haem biosynthetic pathway. When administered exogenously, it is selectively taken up by tumor and pre-malignant cells and metabolized to protoporphyrin IX (PpIX), a potent endogenous photosensitizer. The biochemical basis for this selectivity lies in two enzymatic imbalances characteristic of neoplastic cells: elevated porphobilinogen deaminase (PBGD) activity accelerates PpIX synthesis, while reduced ferrochelatase activity slows PpIX conversion to haem — causing selective PpIX accumulation. Upon illumination with appropriate light wavelengths (typically 630–635 nm red light), the accumulated PpIX generates singlet oxygen (¹O₂) and reactive oxygen species (ROS) that trigger targeted apoptosis and disrupt tumor neovasculature.

The mechanistic link between ALA's existing indications and the broader category of pre-malignant neoplasms is compelling. Actinic keratosis — one of ALA's already-approved indications — is itself a pre-malignant skin condition, meaning the drug has already demonstrated efficacy within this disease category. The same PpIX-accumulation mechanism applies across a spectrum of pre-malignant epithelial tissues including oral mucosa (leukoplakia, erythroplakia), esophageal epithelium (Barrett's esophagus), cervical epithelium, and colonic polyps. A 2016 mechanistic study (PMID 27150264) further identified eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) as a molecular chaperone that actively binds and enriches PpIX within cancer cells, providing a molecular explanation for tumor selectivity across diverse tissue types.

Practical application of this mechanism extends across multiple anatomical sites through adaptable delivery routes: topical cream or gel for skin and oral mucosa, oral solution for systemic distribution and photodynamic diagnosis, intravesical instillation for bladder lesions, and endoscopic or intracavitary delivery for gastrointestinal pre-malignancies. This formulation versatility, combined with the mechanistically consistent PpIX accumulation across pre-malignant epithelial cells, renders the TxGNN prediction biologically robust and clinically translatable.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01497951	Phase 3	Completed	28	Randomized controlled trial of PDT vs placebo for premalignant mucosal oral lesions; most directly relevant evidence — ALA-PDT vs sham in oral pre-malignancy with long-term follow-up through 2017
NCT03638622	Phase 1/2	Completed	30	Low-cost image-guided ALA-PDT for oral pre-malignant lesions (India); evaluates feasibility of photodynamic screening and treatment in resource-limited settings — directly targets pre-malignant oral lesions
NCT06507644	N/A	Not Yet Recruiting	144	Double-blind RCT comparing MAL (ALA methyl ester prodrug) 8% vs 16% with 1 or 3 hour incubation for facial actinic keratoses; rigorous 4-arm design with 6-month follow-up in skin pre-malignancy
NCT00241670	Phase 3	Completed	415	Landmark Phase 3 RCT of fluorescence-guided resection with 5-ALA vs conventional resection in malignant gliomas; established ALA as a tumor-selective photosensitizer in brain oncology
NCT01167322	Phase 3	Completed	45	Assessment of NPC-07 (5-ALA HCl) positive predictive value, safety, and pharmacokinetics in malignant glioma (WHO Grade III/IV); 20 mg/kg oral dose 3 hours pre-surgery
NCT06160492	Phase 3	Recruiting	144	Randomized multicenter Phase 3 trial of 5-ALA fluorescence-guided microsurgery vs white light microsurgical resection in WHO Grade 3/4 malignant gliomas
NCT02191488	Phase 1	Active, Not Recruiting	540	Large-scale safety and pharmacodynamics study quantifying ALA-induced PpIX fluorescence during brain tumor resection; establishes the safety baseline for ALA fluorescence applications
NCT06876038	Phase 2	Not Yet Recruiting	65	Comprehensive low-cost screening and image-guided PDT platform for pre-malignant and malignant oral lesions in low-resource settings; directly targets oral pre-malignancy
NCT00285701	Phase 1/2	Completed	38	Dose-finding study of hexaminolevulinate (HAL, an ALA hexyl ester) for fluorescence endoscopy to detect pre-malignant and malignant colonic conditions; directly supports pre-malignant neoplasm detection
NCT02050243	Phase 1/2	Unknown	100	ALA as intraoperative tumor marker for pediatric CNS tumors; demonstrates ALA-PpIX fluorescence applicability across pediatric tumor histologies

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40614840	2025	RCT (10-yr follow-up)	Photodiagnosis Photodyn Ther	Long-term RCT comparing ALA-PDT, MAL-PDT, and surgery for BCC and pre-malignant lesions; confirms durable efficacy of ALA-based PDT over 10 years in skin pre-malignancy
25315968	2015	Systematic Review	Photodiagnosis Photodyn Ther	Systematic review of PDT efficacy for oral premalignant lesions; highest-tier evidence directly supporting ALA-PDT for oral pre-malignancy management
26516853	2015	Review	Int J Mol Sci	Comprehensive review of combined PDT treatment strategies for non-melanoma skin cancer and pre-malignant lesions (actinic keratosis, Bowen's disease, BCC)
18389144	2008	Review	Photochem Photobiol Sci	Bench-to-bedside review of ALA's clinical applications across dermatology, urology, neurosurgery, gynecology, and gastroenterology for both pre-malignant and malignant diseases
27150264	2016	Mechanistic Study	Scientific Reports	Identifies eEF1A1 as the molecular mechanism that selectively binds and enriches PpIX within cancer cells; explains the tumor selectivity of ALA-PDT at the molecular level
9744510	1998	Clinical-Mechanistic	Br J Cancer	Biochemical basis of ALA-induced PpIX accumulation in (pre)malignant esophageal lesions including Barrett's esophagus; directly measures PBGD and ferrochelatase activities explaining tumor selectivity
39566196	2024	Review/Commentary	Photodiagnosis Photodyn Ther	Clinical review of PDT for early and recurrent oral cancers and pre-malignant lesions; highlights field cancerization treatment potential of ALA in high-prevalence populations
16879035	2006	Clinical Pilot	Photochem Photobiol	In vivo dosimetry study of ALA-PDT for pre-malignant Barrett's esophagus; establishes PpIX fluorescence photobleaching kinetics critical for treatment dosing
31364444	2019	Case Report	J Int Med Res	ALA-PDT successfully treats vulvar intraepithelial neoplasia (VIN) — a pre-malignant gynecological condition — demonstrating applicability in non-dermatological pre-malignancy
22594985	2012	Comparative Clinical Study	Photodiagnosis Photodyn Ther	Direct comparison of ALA-PDT (n=48) vs cryotherapy (n=37) for oral leukoplakia, a pre-malignant lesion; ALA-PDT demonstrated comparable complete response rates with better tolerability

Singapore Market Information

Aminolevulinic acid (5-ALA) currently holds no product registrations with the Singapore Health Sciences Authority (HSA). The drug is not commercially available through authorized channels in Singapore, and there is no local prescribing information or regulatory labeling to reference.

For context, 5-ALA has received approvals in other major jurisdictions:

Jurisdiction	Product Name	Form	Approved Indication
USA (FDA)	Levulan® Kerastick	Topical solution 20%	Actinic keratosis (non-hyperkeratotic, face/scalp) in combination with BLU-U photodynamic illumination
USA (FDA)	Gleolan®	Oral solution powder, 30 mg/mL	Visualization of malignant tissue during fluorescence-guided surgery of high-grade glioma
EU (EMA)	Gliolan®	Oral solution powder, 30 mg/mL	Malignant glioma — adult patients with suspected malignant glioma undergoing surgery
EU (EMA)	Ameluz®	Gel 78 mg/g	Actinic keratosis (mild-to-moderate) and superficial/nodular basal cell carcinoma

Any clinical use in Singapore would require either HSA special access authorization, compassionate use application, or importation under the Personal Importation Exemption framework.

Cytotoxicity

5-ALA functions as a photodynamic therapy (PDT) agent used in the management of pre-malignant and malignant neoplasms. While not a conventional cytotoxic chemotherapy, it produces targeted cytotoxic effects in neoplastic tissue through photochemical mechanisms:

Item	Content
Cytotoxicity Classification	Photosensitizer / Photodynamic Therapy (PDT) Agent — not a conventional cytotoxic; selectively generates reactive oxygen species (¹O₂, ROS) in PpIX-accumulating cells upon light activation
Myelosuppression Risk	Low — mechanism is photochemical and anatomically localized to illuminated tissue; systemic myelosuppression is not a reported concern
Emetogenicity Classification	Low — oral administration may produce mild transient nausea; primary adverse effects are photosensitivity reactions rather than emesis
Monitoring Items	Liver function tests (ALT, AST, bilirubin) prior to oral administration; skin photosensitivity status for 24–48 hours post-dose; ophthalmologic protection (UV-blocking glasses) required
Handling Protection	Standard photosensitizer precautions: protect prepared solution from light; instruct patients to avoid bright sunlight and strong indoor lighting for minimum 24 hours after oral administration; no specialized cytotoxic handling infrastructure required

Safety Considerations

All Singapore-specific safety data are unavailable as the drug is not registered locally. Based on international prescribing information (Gleolan®/Levulan®):

Photosensitivity: Patients must avoid exposure to bright sunlight or intense indoor lighting for at least 24 hours post-administration; phototoxic skin reactions (erythema, burning, stinging) are the primary adverse effect
Hepatotoxicity: Transient liver enzyme elevations have been reported; pre-existing hepatic impairment may increase systemic exposure — liver function monitoring is recommended before dosing
Cardiovascular: Transient hypotension has been observed during or shortly after oral administration in some patients undergoing surgical procedures

Please refer to the full international package insert for Gleolan® or Levulan® for complete warnings, contraindications, and drug interaction information before any clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: 5-ALA has a completed Phase 3 RCT directly in pre-malignant oral lesions (NCT01497951), systematic review evidence supporting oral pre-malignancy treatment, existing FDA/EMA approvals for related conditions (actinic keratosis, malignant glioma), and a well-characterized mechanistic basis for tumor-selective PpIX accumulation. The TxGNN prediction score of 96.01% reflects the drug's established biological plausibility across pre-malignant neoplasm categories. The primary barrier to clinical implementation in Singapore is the complete absence of local registration — not a lack of scientific evidence.

To proceed, the following is needed:

Regulatory pathway: Apply to HSA for special access scheme (SAS) or compassionate use authorization for an appropriate 5-ALA formulation
Formulation selection: Determine whether topical (oral/skin pre-malignant lesions) or oral solution (systemic photodynamic diagnosis/therapy) is appropriate for the intended clinical indication
Full safety review: Obtain and formally review international package inserts for Gleolan® and/or Levulan®/Ameluz® covering contraindications, warnings, and drug interactions
MOA documentation: Retrieve DrugBank API records (DB00855) to formally document mechanism of action for regulatory dossier
Light source assessment: Confirm availability of appropriate photodynamic therapy light sources (630–635 nm red light or 417 nm blue light LED/laser system) in the target clinical facility
Clinical protocol development: Define site-specific dosing protocol including ALA dose (typically 20 mg/kg oral or topical 20% concentration), incubation time (1–3 hours topical; 3 hours oral), light dose (typically 75–100 J/cm²), and follow-up schedule tailored to the target pre-malignant indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.